首页> 外文期刊>British Journal of Clinical Pharmacology >New genetic variant that might improve warfarin dose prediction in African Americans.
【24h】

New genetic variant that might improve warfarin dose prediction in African Americans.

机译:新的遗传变异可能会改善非洲裔美国人对华法林剂量的预测。

获取原文
获取原文并翻译 | 示例
       

摘要

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Variants in the CYP2C9 (i.e. *2 and *3) and VKORC1 (i.e. 1173C/T or -1639G/A) genes have been shown to influence warfarin dose requirements. However, these factors seem to explain less of the dose variability in African Americans who have a lower prevalence of the CYP2C9*2 and *3 and VKORC1 1173T alleles. WHAT THIS STUDY ADDS: In African Americans, the VKORC1 rs17886199 variant was statistically significantly associated with log-transformed warfarin maintenance dose, independent of the influence of VKORC1 1173C>T and CYP2C9*2 and *3. However, replication of our finding is needed to confirm the association of rs1786199 SNP in African Americans, since Limdi et al.[3] did not examine the effect of this SNP because the prevalence of the rs1786199 A-allele was too low. AIMS: To raise hypotheses with regards to whether genetic variants in the VKORC1, CYP2C9, EPHX1, GGCX and ALB genes might influence warfarin dose in African Americans and Caucasians, independent of the effects of the VKORC1 1173C>T and CYP2C9*2 and *3 variants. METHODS: From a prospective cohort study, we obtained additional DNA on 36 Caucasian and 22 African American warfarin users who reached maintenance dose and genotyped them for tagSNPs (r2<0.8) in VKORC1, EPHX1, GGCX and ALB genes, and one exonic CYP2C9 SNP. Linear regression models were fitted to estimate the relationship (P value) between log-transformed maintenance dose and each SNP and the amount of the warfarin dose variability accounted for by each SNP (partial R2). RESULTS: In African Americans, the VKORC1 rs17886199 A-allele was associated with a lower dose (GG=46.3 mg and GA=25.6 mg; P=0.002), independent of the VKORC1 1173C>T and CYP2C9*2 and *3 variants. Even after applying Bonferroni correction, the P value would still be considered statistically significant. The VKORC1 rs17886199 variant was not found in Caucasians. In Caucasians, the EPHX1 rs1051741 T-allele was associated with a lower dose (CC=41.3 mg and CT=30.0 mg; P=0.04). The latter was no longer statistically significant after applying Bonferroni correction. CONCLUSIONS: Our pilot study suggests that the VKORC1 rs17886199 variant could influence warfarin maintenance dose among African Americans, even after accounting for the influence of the VKORC1 1173C>T variant. Future studies with a larger sample size will be needed to confirm our findings.
机译:该受试者已经知道的是:CYP2C9(即* 2和* 3)和VKORC1(即1173C / T或-1639G / A)基因的变体已显示出影响华法林剂量的要求。但是,这些因素似乎较少解释了CYP2C9 * 2和* 3和VKORC1 1173T等位基因患病率较低的非裔美国人的剂量变异性。在非裔美国人中,VKORC1 rs17886199变体与对数转化的华法林维持剂量在统计学上显着相关,不受VKORC1 1173C> T和CYP2C9 * 2和* 3的影响。然而,由于Limdi等[3]的缘故,需要复制我们的发现以确认rs1786199 SNP在非裔美国人中的关联。由于rs1786199 A等位基因的患病率太低,因此未检查该SNP的作用。目的:提出关于VKORC1,CYP2C9,EPHX1,GGCX和ALB基因的遗传变异是否会影响非裔美国人和高加索人中华法林剂量的假设,与VKORC1 1173C> T和CYP2C9 * 2和* 3的影响无关变体。方法:从一项前瞻性队列研究中,我们获得了达到维持剂量的36位白种人和22位非裔美国华法林使用者的其他DNA,并对他们的VKORC1,EPHX1,GGCX和ALB基因以及一个外显子CYP2C9 SNP的tagSNP(r2 <0.8)进行了基因分型。 。拟合线性回归模型以估计对数转换的维持剂量与每个SNP之间的关系(P值)以及每个SNP所占的华法林剂量变异性的量(部分R2)。结果:在非洲裔美国人中,VKORC1 rs17886199 A等位基因与较低剂量(GG = 46.3 mg和GA = 25.6 mg; P = 0.002)相关,与VKORC1 1173C> T和CYP2C9 * 2和* 3变体无关。即使在应用Bonferroni校正之后,仍将P值视为具有统计意义。在白种人中找不到VKORC1 rs17886199变体。在高加索人中,EPHX1 rs1051741 T等位基因与较低剂量有关(CC = 41.3 mg和CT = 30.0 mg; P = 0.04)。应用Bonferroni校正后,后者不再具有统计学意义。结论:我们的初步研究表明,即使考虑了VKORC1 1173C> T变体的影响,VKORC1 rs17886199变体也可能影响非洲裔美国人的华法林维持剂量。未来需要更大样本量的研究来证实我们的发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号